Fotemustine
 | |
| Clinical data | |
|---|---|
| Trade names | Mustophoran |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy category |
|
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
JSmol) | |
| |
| |
  (what is this?) (verify) | |
Fotemustine is a
metastatic melanoma. It is available in Europe but has not been approved by the United States FDA.[1] A study[2] has shown that fotemustine produces improved response rates and but does not increase survival (over dacarbazine
in the treatment of disseminated cutaneous melanoma. Median survival was 7.3 months with fotemustine versus 5.6 months with DTIC (P=.067). There was also toxicity prevalence in fotemustine arm. The main toxicity was grade 3 to 4 neutropenia (51% with fotemustine v 5% with DTIC) and thrombocytopenia (43% v 6%, respectively).